Danish scientists uncovered compelling evidence that a significant percentage of the batches of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine distributed in the EU likely consisted of placebos — and the non-placebo batches demonstrated higher-than-normal severe adverse events in recipients.
The scientists published their study in March, as a letter submitted to the European Journal of Clinical Investigation. BNT162b2 is the vaccine granted Emergency Use Authorization from the U.S. Food and Drug Administration and other authorities.
The study initially did not attract attention, but recent media reports brought it to light.